DelMar Pharmaceuticals EBIT

DelMar Pharmaceuticals (DMPWW) currently reports a EBIT of $0 as of June 2026. That compares with $-4.6M in the prior-year period — up 100.0% year over year. That is below the Materials sector average of $540B. Use the charts on this page to explore DelMar Pharmaceuticals's EBIT history and peer comparisons.

DelMar Pharmaceuticals's EBIT increased from $-4.6M to $0 — a 100.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

DelMar Pharmaceuticals's EBIT of $0 is lower than the Materials sector average of $540B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

DelMar Pharmaceuticals reported $0 in EBIT as of June 2026. That compares with $-4.6M in the prior-year period — up 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is $540B. From there, open related valuation or income-statement pages for DelMar Pharmaceuticals, and consider following DMPWW for alerts when major investors trade the stock.